CORDIS
EU research results

CORDIS

English EN

Multi-modal, Endoscopic Biophotonic Imaging of Bladder Cancer for Point-of-Care Diagnosis

Project information

Grant agreement ID: 667933

Status

Ongoing project

  • Start date

    1 January 2016

  • End date

    31 December 2020

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 5 983 807,50

  • EU contribution

    € 5 983 807,50

Coordinated by:

DANMARKS TEKNISKE UNIVERSITET

Denmark

Objective

Bladder cancer is among the most expensive diseases in oncology in terms of treatment costs; each procedure requires days of hospitalisation and recurrence rates are high. Current unmet clinical needs can be addressed by optical methods due to the combination of non-invasive and real-time capture of unprecedented biomedical information.
The MIB objective is to provide robust, easy-to-use, cost-effective optical methods with superior sensitivity and specificity to enable a step-change in point-of-care diagnostics of bladder cancer. The concept relies on combining optical methods (optical coherence tomography, multi-spectral opto-acoustic tomography, shifted excitation Raman difference spectroscopy, and multiphoton microscopy) providing structural, biochemical and functional information. The hypothesis is that such combination enables in situ diagnosis of bladder cancer with superior sensitivity and specificity due to unprecedented combined anatomic, biochemical and molecular tissue information. The step-change is that this hybrid concept is provided endoscopically for in vivo clinical use.
The project relies on development of new light sources, high-speed imaging systems, unique imaging fibre bundles, and endoscopes, combined and applied clinically. The consortium comprises world-leading academic organisations in a strong partnership with innovative SMEs and clinical end-users.
Through commercialization of this novel imaging platform, MIB is expected to reinforce leading market positions in medical devices and healthcare for the SMEs in areas where European industry is already strong. The impact is that improved diagnostic procedures facilitate earlier onset of effective treatment, thus recurrence and follow-up procedures would be reduced by 10%, i.e., reducing costs. Using MIB technology, healthcare cost savings in the order of 360M€ are expected for the whole EU. Equally important, prognosis and patient quality of life would improve drastically.

Coordinator

DANMARKS TEKNISKE UNIVERSITET

Address

Anker Engelundsvej 1 Bygning 101 A
2800 Kgs Lyngby

Denmark

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 829 254,50

Participants (10)

FORSCHUNGSVERBUND BERLIN EV

Germany

EU Contribution

€ 669 582,50

M-SQUARED LASERS LIMITED

United Kingdom

EU Contribution

€ 512 500

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 689 078

Blazejewski MEDI-TECH GMBH

Germany

EU Contribution

€ 432 812,50

LEIBNIZ-INSTITUT FUER PHOTONISCHE TECHNOLOGIEN E.V.

Germany

EU Contribution

€ 653 875

GRINTECH GMBH

Germany

EU Contribution

€ 365 475

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 479 081,25

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

EU Contribution

€ 655 046,25

2M ENGINEERING LIMITED

United Kingdom

EU Contribution

€ 502 102,50

ALBERT-LUDWIGS-UNIVERSITAET FREIBURG

Germany

EU Contribution

€ 195 000

Project information

Grant agreement ID: 667933

Status

Ongoing project

  • Start date

    1 January 2016

  • End date

    31 December 2020

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 5 983 807,50

  • EU contribution

    € 5 983 807,50

Coordinated by:

DANMARKS TEKNISKE UNIVERSITET

Denmark